Literature DB >> 29784160

Systemic medication usage in glaucoma patients.

Tenley Bower1, Deborah Anne Samek2, Ahmed Mohammed3, Ali Mohammed3, Paul Kasner4, David Camoriano1, Oscar Kasner5.   

Abstract

OBJECTIVE: To study the prevalence of the systemic use of some common classes of medications by glaucoma patients and their relationship to the prevalence and severity of chronic open-angle glaucoma (COAG) and primary-angle closure glaucoma (PACG).
DESIGN: Observational prospective single-centre cross-sectional study.
METHODS: Glaucoma patients or their pharmacist provided an updated list of all systemic medications that they presently use. The relationship between glaucoma type and severity and medication use for diseases other than glaucoma was assessed by univariate statistics.
RESULTS: We studied 514 glaucoma patients. They use a mean of 4.9 oral medications prescribed by a mean of 2.1 doctors. Antihypertensives, medications with anticholinergic properties, steroids, anticoagulants, and thyroid hormones were the most frequently prescribed groups of medications, used by 251 (49%), 178 (35%), 100 (19%), 218 (42%), and 108 (21%) patients, respectively. Steroid usage was associated with advanced visual field loss in COAG patients. Antihypertensives and medications with anticholinergic properties were not associated with severity of COAG and PACG, respectively, and these 3 groups were not associated with an increased prevalence of diagnosis of COAG or PACG.
CONCLUSION: Glaucoma patients take many systemic medications in addition to their topical glaucoma treatment.
Copyright © 2018 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29784160     DOI: 10.1016/j.jcjo.2017.10.029

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  1 in total

1.  Potentially inappropriate prescriptions of anticholinergic medications in patients with closed-angle glaucoma.

Authors:  Luis Fernando Valladales-Restrepo; Jorge Enrique Machado-Alba
Journal:  Int Ophthalmol       Date:  2019-12-03       Impact factor: 2.031

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.